Business Description
Acasti Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA00430K4028
Share Class Description:
ACST: Class ACompare
Compare
Traded in other countries / regions
ACST.USAA1P0.GermanyACST.Canada IPO Date
2011-04-26Description
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1046.42 | |||||
| Equity-to-Asset | 0.85 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 42.8 | |||||
| 3-Year EPS without NRI Growth Rate | 47.7 | |||||
| 3-Year FCF Growth Rate | 45.5 | |||||
| 3-Year Book Growth Rate | 9.7 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 2.59 | |||||
| 9-Day RSI | 10.7 | |||||
| 14-Day RSI | 25.21 | |||||
| 6-1 Month Momentum % | 30.27 | |||||
| 12-1 Month Momentum % | 18.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.19 | |||||
| Quick Ratio | 15.19 | |||||
| Cash Ratio | 14.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -58.2 | |||||
| Shareholder Yield % | -23.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -53.84 | |||||
| ROA % | -45.79 | |||||
| ROIC % | -17.36 | |||||
| ROC (Joel Greenblatt) % | -4341.47 | |||||
| ROCE % | -14.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 1.87 | |||||
| EV-to-EBIT | -0.4 | |||||
| EV-to-EBITDA | -0.4 | |||||
| EV-to-FCF | -0.36 | |||||
| Price-to-Net-Current-Asset-Value | 1.87 | |||||
| Price-to-Net-Cash | 2.12 | |||||
| Earnings Yield (Greenblatt) % | -250 | |||||
| FCF Yield % | -47.06 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers